Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Autoinflammatory disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Treatment of diseases using ICE inhibitors
Owner:VERTEX PHARMA INC
Ras inhibitors and uses thereof
Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.
Owner:DANA FARBER CANCER INST INC
Method to diagnose or screen for inflammatory diseases
The invention relates to the field of medical diagnostics. More specifically, the invention relates to methods to diagnose or screen for inflammatory conditions or disease, including auto-inflammatory disease and affective disorder, in a subject, preferably a human subject, by assaying for a marker for an inflammatory disease. Provided is a method to diagnose, screen for or predict the development of an affective disorder (AD), preferably bipolar disorder (BP), in a subject, the method comprising determining the level of at least one, preferably at least two, more preferably at least three, most preferred at least four, AD-specific gene product(s) in a biological sample isolated from the subject, preferably peripheral blood monocytes, wherein the gene is selected from the group comprising ATF3, phosphodiesterase 4 B, CXCL2, BCL2-related protein A2, Dual specificity phosphatase 2, TNFα-induced protein 3 / A20, BTEB1 CXCL3, Chemokine CCL-3 like, CCL-4, CCL20, CX2CR1, Amphiregulin, Thrombomodulin, Heparin-binding EGF-like growth factor, DNA-damaged inducible transcript, V28 chemokine-like receptor, TRAIL. MAPK6, B4BP4, PBEF1, Thrombospondin 1, MAFF, HSP70, CCL2, MCP-3, CCR2, CX3CR1, DOK1, HBB, G-gamma globin, THBD, PHLDA1, DTR and GNLY.
Owner:ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC
Heteroaromatic compounds useful for the treatment of prolferative diseases
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, in duce cellular apoptosis and / or inhibit transcription in the subject.
Owner:SYROS PHARMACEUTICALIS INC +1
Heteromaromatic compounds useful for the treatment of prolferative diseases
InactiveUS20160264552A1Improve efficacyPrevent relapseOrganic active ingredientsOrganic chemistryAutoimmune conditionStage melanoma
The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject. (I)
Owner:SYROS PHARMACEUTICALIS INC
Inhibitors of cyclin dependnt kinase 7 (CDK7)
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benignneoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition ofthe invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.
Owner:SYROS PHARMACEUTICALIS INC
Heteroaromatic compounds useful for the treatment of proliferative diseases
ActiveUS20190241541A1Improve efficacyPrevent relapseOrganic active ingredientsOrganic chemistryDiseaseMelanoma
Owner:SYROS PHARMACEUTICALIS INC +1
Inhibitors of cyclin-dependent kinase 7 (CDK7)
ActiveUS20170183355A1Improve efficacyPrevent relapseOrganic active ingredientsOrganic chemistryAutoimmune conditionStage melanoma
The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.
Owner:SYROS PHARMACEUTICALIS INC
Inhibitors of cyclin-dependent kinase 7 (CDK7)
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase (e.g., CDK7), and therefore induce cellular apoptosis and / or inhibit transcription in the subject.
Owner:SYROS PHARMACEUTICALIS INC
Mitochondrial nucleic acid as a marker for autoimmune and autoinflammatory diseases
ActiveUS20140099648A1Easy to determineIncrease probabilityMicrobiological testing/measurementAutoimmune conditionAutoimmune disease
The present invention relates to a method for increasing the diagnostic likelihood of the presence or absence of, or monitoring the progression or activity of an inflammatory autoimmune disease (AID), comprising detecting mitochondrial NA (e.g. mtDNA) in a sample from an individual suffering from the AID or suspected of suffering from the AID.
Owner:UNIVERSITATSKLINIKUM FREIBURG
Antibody conjugates of immune-modulatory compounds and uses thereof
InactiveUS20200199247A1Reduced activityHigh activitySkeletal disorderImmunoglobulins against growth factorsImmunologic disordersAutoimmune condition
Antibody conjugates of immune-modulatory compounds and pharmaceutical compositions for use in the treatment of disease, such as fibrotic diseases, autoimmune, or autoinflammatory diseases, are disclosed herein. The disclosed conjugates are useful, among other things, in treating fibrotic diseases, autoimmune diseases, or autoinflammatory diseases, such as by modulating TGFβR1, TGFβR2, TNKS, TNIK, or mTOR.
Owner:SILVERBACK THERAPEUTICS INC
Probe set and kit for detecting pathogenic gene of autoinflammatory disease
ActiveCN109371123AHigh sensitivityImprove featuresMicrobiological testing/measurementDNA/RNA fragmentationAuto inflammatory diseaseMissed diagnosis
The invention provides a probe set and a kit for detecting a pathogenic gene of an autoinflammatory disease. The probe set comprises probes capable of simultaneously specifically capturing pathogenicgenes affecting inflammasome defects, non-inflammasome defects and autoinflammatory diseases associated with defects in an interferon pathway. The probe set and the kit for detecting the pathogenic gene of the autoinflammatory disease are capable of simultaneously detecting the pathogenic genes of 50 types of known autoinflammatory diseases; based on the probe set which is high in targeted screening, stable and reliable in gene acquisition and used for detecting the pathogenic gene of the autoinflammatory disease, and combined with a high-throughput sequencing method, a diagnosis cycle of theautoinflammatory disease can be accelerated, the diagnostic efficiency can be improved, and several new diseases can be diagnosed, especially for children with the autoinflammatory diseases, so that the effects of no missed detection, no missed diagnosis, relatively small amount of data analysis, shortened inspection cycle are achieved.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Inhibitors of cyclin-dependent kinase 7 (CDK7)
ActiveUS10336760B2Improve efficacyAvoid adjustmentOrganic chemistryAntineoplastic agentsDiseaseMelanoma
Owner:SYROS PHARMACEUTICALIS INC
Inhibitors of cyclin-dependent kinase 7 (CDK7)
Owner:SYROS PHARMACEUTICALIS INC
Treatment of diseases using ICE inhibitors
Owner:VERTEX PHARMA INC
Heteroaromatic compounds useful for the treatment of proliferative diseases
InactiveUS20190292167A1Improve efficacyPrevent relapseOrganic active ingredientsOrganic chemistryAutoimmune conditionStage melanoma
Owner:SYROS PHARMACEUTICALIS INC
Inhibitors of cyclin-dependent kinase 7 (CDK7)
ActiveUS20180208578A1Improve efficacyPrevent relapseOrganic active ingredientsOrganic chemistryMelanomaAutoimmune disease
The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.
Owner:SYROS PHARMACEUTICALIS INC
Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
ActiveUS20210317105A9Reduces and avoids symptom and causeGood curative effectOrganic chemistryAntineoplastic agentsAutoimmune conditionStage melanoma
Owner:DANA FARBER CANCER INST INC
Ionizable lipidoids and their uses
ActiveUS20200109121A1Reduce deliveryInhibit tumor growthOrganic chemistryAntipyreticAutoimmune conditionAutoimmune disease
Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and / or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a cell.
Owner:MASSACHUSETTS INST OF TECH
Fused bicyclic pyrimidine derivatives and uses thereof
ActiveUS20180369243A9Good curative effectDelay moreOrganic chemistryAntineoplastic agentsAutoimmune conditionIsotopic labeling
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase (e.g. a protein kinase (e.g. a cyclin-dependent kinase (CDK) (e.g. CDK7, CDK12, or CDK13) or a lipid kinase such as a phosphatidylinositol-5-phosphate 4-kinase (PIP4K) (e.g., PI5P4Kα, PI5P4Kβ, or PI5P4Kγ)) in the subject.
Owner:DANA FARBER CANCER INST INC
Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PendingUS20220340548A1Organic active ingredientsSenses disorderImmunologic disordersAutoimmune condition
The present invention discloses compounds according to Formula I:wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein.The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, dermatological diseases, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.
Owner:GALAPAGOS NV
Antibody conjugates of immune-modulatory compounds and uses thereof
PendingCN110891605ASkeletal disorderImmunoglobulins against growth factorsAutoimmune conditionAntiendomysial antibodies
Owner:SILVERBACK THERAPEUTICS INC
Compounds and pharmaceutical compositions thereof for the treatment of diseases
ActiveUS11339166B2Proportion of an uncommon isotope has been reducedReduce the ratioOrganic active ingredientsOrganic chemistryImmunologic disordersAutoimmune condition
Owner:GALAPAGOS NV
Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
ActiveUS20200361906A1Convenient treatmentReduces and avoids symptomOrganic chemistryAntineoplastic agentsAutoimmune conditionStage melanoma
The present invention provides novel compounds of Formulae (I′) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK12), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.
Owner:DANA FARBER CANCER INST INC
Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
ActiveUS20210169879A1High selectivitySimple designOrganic active ingredientsAntipyreticImmunologic disordersAutoimmune condition
The present invention discloses compounds according to Formula I:Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein.The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and / or diseases associated with hypersecretion of IFNα, IL12 and / or IL23 by administering the compound of the invention.
Owner:GALAPAGOS NV
Methyl/fluoro-pyridyl-methoxy substituted pyridone-pyridyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridone-pyridyl compounds
The present disclosure provides methyl / fluoro-pyridyl-methoxy substituted pyridinone-pyridyl for use in the treatment of p38 kinase-mediated diseases, such as lymphoma and autoinflammatory diseases, including rheumatoid arthritis. Compounds and fluoro-pyrimidinyl-methoxy substituted pyridone-pyridyl compounds, which have the structure of formula (I): wherein R1, R2, R3, R4, R5 and X are as defined in the detailed description; comprising at least one pharmaceutical compositions of the compounds; and methods of using the compounds for the treatment of p38 kinase-mediated diseases.
Owner:ACLARIS THERAPEUTICS +3
Compounds as nlrp3 inflammasome inhibitors and compositions and uses thereof
Scaffold compounds are used to design small molecule compounds and structure-activity relationship studies identify inhibitors of inflammation. Methods include pharmaceutical compositions of the small molecule compounds to inhibit, prevent and treat diseases and conditions associated with inflammation, including multiple sclerosis, Alzheimer's disease, acute myocardial infarction, traumatic brain injury and autoinflammatory diseases.
Owner:VIRGINIA COMMONWEALTH UNIV
Inhibitors of cyclin-dependent kinase 7 (CDK7)
Owner:SYROS PHARMACEUTICALIS INC
PD-L1 presenting platelets reverse new-onset type 1 diabetes
PendingCN113164523AAlleviate/prevent/suppress diabetesMetabolism disorderGenetically modified cellsGraft versus host disease inductionPlatelet
Owner:NORTH CAROLINA STATE UNIV
Inhibitors of cyclin-dependent kinase 7 (CDK7)
InactiveUS20190330218A1Improve efficacyAvoid adjustmentOrganic chemistryAntineoplastic agentsDiseaseMelanoma
Owner:SYROS PHARMACEUTICALIS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com